Paper Details

  1. Home
  2. Paper Details

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Author: , AgarwalKosh, AngusPeter, ArterburnSarah, BrainardDiana, ButiMaria, CallejaJosé Luis, ColomboMassimo, DenningJill, DufourJean-François, Dvory-SobolHadas, FornsXavier, GaneEdward J, MannsMichael, McCaughanGeoff, McHutchisonJohn G, MutimerDavid, MüllhauptBeat, PangPhillip S, Peck-RadosavljevicMarkus, PrietoMartín, RizzettoMario, SamuelDidier, Van VlierbergheHans, YoshidaEric M, van HoekBart

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Ledipasvir-sofosbuvir and ribavirin showed high rates of sustained virological response 12 weeks after treatment (SVR12) in patients with advanced liver disease, including those with decompensated cirrhosis. This provides a promising treatment option for patients with limited treatment options.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment options are limited for patients infected by hepatitis C virus (HCV) with advanced liver disease. We assessed the safety and efficacy of ledipasvir, sofosbuvir, and ribavirin in patients with HCV genotype 1 or 4 and advanced liver disease. METHODS: We did an open-label study a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1473-3099(16)00052-9

データ提供：米国国立医学図書館（NLM）

Ledipasvir and Sofosbuvir: A New Oasis in the Desert of Hepatitis C

Hepatitis C virus (HCV) infection can be a real challenge, like trying to survive a long trek across a scorching desert. This research explores the effectiveness of a new combination therapy – ledipasvir and sofosbuvir, with or without ribavirin – in treating patients with advanced liver disease. The study found that this combination was highly effective in achieving sustained virological response (SVR) in patients with genotype 1 or 4 HCV infection and advanced liver disease. This combination is like a well-stocked caravan, providing a safe and effective path toward recovery.

A New Road to Recovery: Ledipasvir and Sofosbuvir for Hepatitis C

This study suggests that ledipasvir and sofosbuvir, with or without ribavirin, are a safe and effective treatment option for patients with HCV infection and advanced liver disease. It's like discovering a new, paved road through the desert, making the journey to recovery smoother and less arduous.

Navigating the Desert of Hepatitis C: Hope for Patients with Advanced Liver Disease

This research provides valuable information about the effectiveness of ledipasvir and sofosbuvir in treating patients with HCV and advanced liver disease. It's like finding a map that guides us to a safe and accessible oasis in the middle of a vast desert.

Dr.Camel's Conclusion

This research showcases the effectiveness of ledipasvir and sofosbuvir in treating HCV infection in patients with advanced liver disease. This combination is a promising tool in the fight against HCV, offering a ray of hope in the desert of viral infections.

Date :
  1. Date Completed 2017-06-05
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

26907736

DOI: Digital Object Identifier

10.1016/S1473-3099(16)00052-9

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.